hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06372652, orgStudyIdInfo id: TE-8214-001, briefTitle: A Phase 1 Study of TE-8214 Solution in Healthy Volunteers, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-02, primaryCompletionDateStruct date: 2024-10-10, completionDateStruct date: 2024-12-26, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Immunwork, Inc., class: INDUSTRY, descriptionModule briefSummary: This is a Phase 1, first-in-human, randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, and PK of TE-8214 in healthy volunteers. The study will assess single ascending doses (SAD) of TE-8214., conditionsModule conditions: Acromegaly, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 32, type: ESTIMATED, armsInterventionsModule interventions name: TE-8214 - SAD, interventions name: Placebo, outcomesModule primaryOutcomes measure: Safety and tolerability of TE-8214 by the incidence of treatment-emergent adverse events (TEAEs), primaryOutcomes measure: Safety and tolerability of TE-8214 by the incidence of treatment-related adverse events, primaryOutcomes measure: Safety and tolerability of TE-8214 by the incidence of injection site reactions (ISRs), primaryOutcomes measure: Safety and tolerability of TE-8214 by the incidence of clinically significant laboratory findings, primaryOutcomes measure: Safety and tolerability of TE-8214 by the changes in physical examination findings, primaryOutcomes measure: Safety and tolerability of TE-8214 by the changes in ECG findings, secondaryOutcomes measure: PK Parameters: Maximum observed concentration (Cmax), secondaryOutcomes measure: PK Parameters: Time to maximum observed concentration (Tmax), secondaryOutcomes measure: PK Parameters: Area under the concentration-time curve (AUC) from time zero to the last measurable concentration (AUC 0-last), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 64 Years, stdAges: ADULT, contactsLocationsModule locations facility: CMAX Clinical Research, city: Adelaide, state: South Australia, zip: 5000, country: Australia, contacts name: Jessica Gehlert, Dr, role: CONTACT, geoPoint lat: -34.92866, lon: 138.59863, hasResults: False
protocolSection identificationModule nctId: NCT06372639, orgStudyIdInfo id: TAU-PTSD-TMS, briefTitle: Characterization and Modulation of Traumatic Memories in PTSD Patients Using TMS, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-02-23, primaryCompletionDateStruct date: 2024-11-24, completionDateStruct date: 2024-11-24, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Tel Aviv University, class: OTHER, descriptionModule briefSummary: Characterization and modulation of traumatic memories in PTSD patients using TMS., conditionsModule conditions: Post Traumatic Stress Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Trans-Cranial Magnetic Stimulation, outcomesModule primaryOutcomes measure: CAPS-5 score, primaryOutcomes measure: Neurological measures of functional connectivity, primaryOutcomes measure: Intrusive memories, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tel Aviv University, status: RECRUITING, city: Tel Aviv, zip: 69978, country: Israel, contacts name: Yair Bar-Haim, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 32.08088, lon: 34.78057, hasResults: False
protocolSection identificationModule nctId: NCT06372626, orgStudyIdInfo id: ZG005-004, briefTitle: Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08, primaryCompletionDateStruct date: 2026-07, completionDateStruct date: 2026-08, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Suzhou Zelgen Biopharmaceuticals Co.,Ltd, class: INDUSTRY, descriptionModule briefSummary: The trial is divided into two parts. PART 1 is a dose escalation study of the ZG005 combined with Etoposide and Cisplatin, primarily assessing the tolerability and safety of this combined treatment. PART 2 is a dose expansion study, further evaluating the preliminary efficacy and safety of this combined treatment., conditionsModule conditions: Neuroendocrine Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 93, type: ESTIMATED, armsInterventionsModule interventions name: ZG005, interventions name: Etoposide, interventions name: Cisplatin, interventions name: Placebo, outcomesModule primaryOutcomes measure: Dose Limiting Toxicity (DLT), primaryOutcomes measure: Objective Response Rate (ORR), primaryOutcomes measure: Adverse Event (AE), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Chinese PLA General Hospital, city: Beijing, state: Beijing, zip: 100853, country: China, contacts name: Jianming Xu, role: CONTACT, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06372613, orgStudyIdInfo id: LRG&UC, briefTitle: Association Between LRG and Endoscopic Remission in Ulcerative Colitis, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-25, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Showa Inan General Hospital, class: OTHER, descriptionModule briefSummary: We attempt to clarify the serum leucine-rich α 2-glycoprotein (LRG) level which predicts endoscopic remission in ulcerative colitis patients in this study. Colonoscopy with histology is performed when endoscopic remission will be predicted based on serum LRG values, irrespective of symptoms. Serum LRG levels were analyzed by an enzyme-linked immunosorbent assay., conditionsModule conditions: Ulcerative Colitis in Remission, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, outcomesModule primaryOutcomes measure: Endoscopic remission of UC, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Showa Inan General Hospital, status: RECRUITING, city: Komagane, country: Japan, contacts name: Akira Horiuchi, role: CONTACT, geoPoint lat: 35.71657, lon: 137.93745, hasResults: False
protocolSection identificationModule nctId: NCT06372600, orgStudyIdInfo id: 2023-181, briefTitle: Effect of Extracorporeal Shock Wave Combined With Autologous Platelet-rich Plasma Injection on Rotator Cuff Calcific Tendinitis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2025-06-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-02-20, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Xiali Xue, class: OTHER, descriptionModule briefSummary: The purpose of this study is to explore the effect of extracorporeal shock wave combined with autologous platelet-rich plasma injection on the rehabilitation of rotator cuff calcific tendinitis, to provide new treatment methods and evidence for the rehabilitation of rotator cuff calcific tendinitis, and to reduce patients; pain and return to normal life as soon as possible., conditionsModule conditions: Rotator Cuff Tendinitis, conditions: Rotator Cuff Tendinosis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Extracorporeal shock wave therapy device, interventions name: Platelet-rich plasma, outcomesModule primaryOutcomes measure: Visual Analogue Scale,VAS, secondaryOutcomes measure: American Shoulder and Elbow Surgeon's Form,ASES, secondaryOutcomes measure: the university of California at Los Angeles shoulder rating scale, UCLA, secondaryOutcomes measure: The location and size of the calcifications were examined by ultrasound, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06372574, orgStudyIdInfo id: GO44669, briefTitle: A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2028-02-01, completionDateStruct date: 2028-02-01, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Genentech, Inc., class: INDUSTRY, descriptionModule briefSummary: This study will evaluate the safety, tolerability, and pharmacokinetics of RO7617991, and will make a preliminary assessment of the anti-tumor activity of RO7617991 in human leukocyte antigen (HLA)-A\*02 eligible patients with locally advanced or metastatic melanoma-associated antigen A4 (MAGE-A4)-positive solid tumors., conditionsModule conditions: Refractory Cancer, conditions: Recurrent Cancer, conditions: Solid Tumor, Adult, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 210, type: ESTIMATED, armsInterventionsModule interventions name: RO7617991, interventions name: Tocilizumab, outcomesModule primaryOutcomes measure: Incidence and Severity of Adverse Events, primaryOutcomes measure: Number of Participants with Abnormal Values in Targeted Vital Signs, primaryOutcomes measure: Number of Participants with Abnormal Values in Clinical Laboratory Test Parameters, secondaryOutcomes measure: Serum Concentration of RO7617991 at Specific Timepoints, secondaryOutcomes measure: Objective Response Rate (ORR), as Determined by the Investigator According to RECIST v1.1, secondaryOutcomes measure: Duration of Response (DOR), as Determined by the Investigator According to RECIST v1.1, secondaryOutcomes measure: Progression-Free Survival (PFS), as Determined by the Investigator According to RECIST v1.1, secondaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: Prevalence of Anti-Drug Antibodies (ADAs) to RO7617991 at Baseline and Incidence of ADAs to RO7617991 During the Study, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06372561, orgStudyIdInfo id: Melatonin- vital pulp therapy, briefTitle: Comparative Evaluation of Melatonin Versus MTA on Vital Pulp Therapy in Young Permanent First Molars: An in Vivo Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-20, primaryCompletionDateStruct date: 2024-05-20, completionDateStruct date: 2024-06-20, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Suez Canal University, class: OTHER, descriptionModule briefSummary: The process of dental caries is dynamic and can be either reversible or irreversible depending on the balance between protective and pathologic factors in the oral cavity. Untreated dental caries causes pulpal injury, inflammation, and necrosis. Melatonin plays an essential role in the regulation of bone growth. The actions that melatonin exerts on odontoblasts may be similar to its action on osteoblasts., conditionsModule conditions: Dental Caries in Children, conditions: Vital Pulp Therapy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: Mineral trioxide aggregate (dressing material), interventions name: Melatonin (dressing material), outcomesModule primaryOutcomes measure: Clinically assessment (Modified visual analogue scale), primaryOutcomes measure: Clinically assessment (Millar's index), primaryOutcomes measure: Clinically assessment (presence or abscence), primaryOutcomes measure: Radiographic assessment (using Image J software program), primaryOutcomes measure: Radiographic assessment (using Image J software program), primaryOutcomes measure: Radiographic assessment (using Image J software program), primaryOutcomes measure: Radiographic assessment (using Image J software program), primaryOutcomes measure: Radiographic assessment (using Image J software program), eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 8 Years, stdAges: CHILD, contactsLocationsModule locations facility: Faculty of Medicine, Suez canal university, status: RECRUITING, city: Ismailia, zip: 41522, country: Egypt, contacts name: Ismail Dahshan, PHD, role: CONTACT, phone: 01012715799, email: dahshan1633@gmail.com, geoPoint lat: 30.60427, lon: 32.27225, hasResults: False
protocolSection identificationModule nctId: NCT06372548, orgStudyIdInfo id: NEADS0004, briefTitle: Rehabilitation Training Games for Children With Amblyopia, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-03-01, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-08-01, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Zhu Dian, class: OTHER, descriptionModule briefSummary: A gamification product was developed to guide children with amblyopia to develop rehabilitation training habits by combining cognitive evaluation theory and occlusion therapy. A randomized controlled trial was conducted to examine the ease of use, acceptability and treatment compliance of the game., conditionsModule conditions: Amblyopia, conditions: Amblyopia Occlusion, conditions: Child Behavior, conditions: Adherence, Treatment, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 34, type: ESTIMATED, armsInterventionsModule interventions name: Find You! Cure My Animal Friends, interventions name: DuoBao Vision Training System, outcomesModule primaryOutcomes measure: 8-Item Morisky Medication Adherence Scale (MMAS-8):, secondaryOutcomes measure: User Experience Questionnaire (UEQ), eligibilityModule sex: ALL, minimumAge: 7 Years, maximumAge: 10 Years, stdAges: CHILD, contactsLocationsModule locations facility: Shanghai Jiao Tong University, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200240, country: China, contacts name: Zhao Liu, role: CONTACT, phone: +8618901626266, email: hotlz@sjtu.edu.cn, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06372535, orgStudyIdInfo id: FujianUTCM-1, briefTitle: Effects of Tai Chi Chuan With Different Doses on Cognitive Function in Elderly Patients With Mild Cognitive Impairment, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-06-15, completionDateStruct date: 2025-09-30, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Lidian Chen, class: OTHER, collaborators name: Peking University Third Hospital, descriptionModule briefSummary: To determine the impact of Tai Chi Chuan with different exercise volume on cognitive function in elderly patients with mild cognitive impairment., conditionsModule conditions: Mild Cognitive Impairment, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 540, type: ESTIMATED, armsInterventionsModule interventions name: Tai Chi Chuan （dose 1）, interventions name: Tai Chi Chuan （dose 2）, interventions name: Tai Chi Chuan （dose 3）, interventions name: Tai Chi Chuan （dose 4）, interventions name: Tai Chi Chuan （dose 5）, interventions name: Tai Chi Chuan （dose 6）, interventions name: Tai Chi Chuan （dose 7）, interventions name: Tai Chi Chuan （dose 8）, interventions name: Tai Chi Chuan （dose 9）, outcomesModule primaryOutcomes measure: Montreal Cognitive Assessment, secondaryOutcomes measure: Montreal Cognitive Assessment, secondaryOutcomes measure: Wechsler Memory Scale, secondaryOutcomes measure: Digital Symbol test, secondaryOutcomes measure: Trial Making Test part B, secondaryOutcomes measure: Stroop color word test, secondaryOutcomes measure: Boston naming test, secondaryOutcomes measure: Rey-Osterrieth complex graphics test, secondaryOutcomes measure: Rey Auditory Verbal Learning Test, otherOutcomes measure: Blood glucose metabolism index, otherOutcomes measure: Blood lipid metabolism index, otherOutcomes measure: Functional Magnetic Resonance Imaging, otherOutcomes measure: Electroencephalogram, otherOutcomes measure: Heart rate variability, otherOutcomes measure: Gut microflora, otherOutcomes measure: Sleep Quality, otherOutcomes measure: General health, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06372522, orgStudyIdInfo id: RMB-0517-23, briefTitle: Oxytocin in Multiparous Women, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-04, completionDateStruct date: 2027-04, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Rambam Health Care Campus, class: OTHER, descriptionModule briefSummary: This is a randomized controlled trial investigating whether continuous oxytocin infusion in multiparous women shortens time to delivery, without altering maternal or neonatal outcomes, in augmented deliveries, compared to intermittent infusion., conditionsModule conditions: Pregnancy Related, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 166, type: ESTIMATED, armsInterventionsModule interventions name: Pitocin Injectable Product, outcomesModule primaryOutcomes measure: The rate of women delivering within 24 hours., secondaryOutcomes measure: Length of latent and active phases of labor., secondaryOutcomes measure: The rate of instrumental and caesarean deliveries., secondaryOutcomes measure: chorioamnionitis, secondaryOutcomes measure: obstetric anal sphincter injuries (OASIS), secondaryOutcomes measure: hyponatremia, secondaryOutcomes measure: post-partum hemorrhage (PPH), secondaryOutcomes measure: neonatal outcome - 1 and 5-minute Apgar score, secondaryOutcomes measure: umbilical artery pH, secondaryOutcomes measure: NICU admission, secondaryOutcomes measure: Women's satisfaction., eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06372509, orgStudyIdInfo id: L2-070, briefTitle: A Proteomic Analysis for Understanding the Link Between Migraine and Cardiovascular Disease, acronym: PMCD, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-03, primaryCompletionDateStruct date: 2025-10-30, completionDateStruct date: 2025-10-30, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Centro Cardiologico Monzino, class: OTHER, collaborators name: IRCCS Policlinico S. Donato, descriptionModule briefSummary: This is a multicenter, prospective observational study. Will be collecting data from 90 consecutive patients (aged 25- 60 years ) with and without migraine admitted at our Hospital. Primary aim of the study will be to assess the correlation between migraine and proteomic profiling of plasma and their possible correlation with known cardio and cerebrovascular disease and CV risk factors., conditionsModule conditions: Coronary Artery Disease, conditions: Migraine, conditions: Cardiovascular Diseases, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Correlation between migraine and proteomic profiling of plasma, eligibilityModule sex: ALL, minimumAge: 25 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Centro Cardiologico Monzino, status: RECRUITING, city: Milano, state: Milan, zip: 20131, country: Italy, contacts name: Daniela Trabattoni, MD, role: CONTACT, phone: 0258002780, email: daniela.trabattoni@cardiologicomonzino.it, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False